Trials / Unknown
UnknownNCT03267771
Progesterone and Doppler in Recurrent Abortion
Role of Serum Progesterone and Doppler Ultrasound in Prediction of Pregnancy Outcome in Women With Recurrent Unexplained Abortion
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
Recurrent pregnancy loss is classically defined as the occurrence of three or more consecutive pregnancy loss. The American Society of Reproductive Medicine has recently redefined recurrent pregnancy loss as two or more pregnancy losses. A pregnancy loss is defined as a clinically-recognized pregnancy means that the pregnancy has been visualized on an ultrasound or that pregnancy tissue was identified after a pregnancy loss.
Detailed description
Spontaneous pregnancy loss is a surprisingly common occurrence. Whereas approximately 15% of all clinically recognized pregnancies result in spontaneous loss, there are many more pregnancies that fail prior to being clinically recognized. Only 30% of all conceptions result in a live birth. Although no reliable published data have estimated the probability of finding an etiology for recurrent pregnancy loss in a population with 2 versus 3 or more miscarriages, the best available data suggest that the risk of miscarriage in subsequent pregnancies is 30% after 2 losses, compared with 33% after 3 losses among patients without a history of a live birth. This strongly suggests a role for evaluation after just 2 losses in patients with no prior live births. An earlier evaluation may be further indicated if fetal cardiac activity was identified prior to a loss .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Progesterone Suppositories Vaginal | progesterone vaginal suppository |
| DRUG | Dydrogesterone Oral Tablet | oral progesterone drug |
| DEVICE | doppler ultrasound | pulsed doppler ultrasound |
Timeline
- Start date
- 2017-10-01
- Primary completion
- 2019-08-05
- Completion
- 2019-12-05
- First posted
- 2017-08-30
- Last updated
- 2017-09-08
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03267771. Inclusion in this directory is not an endorsement.